Table 2. Univariate analysis of factors associated with liver fibrosis progression.

Factors	OR a, 95% CI b	P value
Age (>35 y at liver biopsy)	0.7 (0.24-2.04)	0.59
Sex (Male)	1.43 (0.43-4.72)	0.7
History of alcohol abuse	2.67 (0.88-8.04)	0.067
ALT c (>150, IU/L at first biopsy)	4.16 (1.22-14.11)	0.02
No interferon treatment	2.35 (0.75-7.36)	0.16
CD4
Nadir, < 200/mmc	2.1 (0.73-6.19)	0.19
At first biopsy, < 350/mmc	0.69 (0.23-2.02)	0.59
Between two biopsies, < 200/mmc	3.37 (0.9-12)	0.06
No ART d, Single or dual NRTIs evs. HAART f
At first biopsy	0.67 (0.1-2.5)	0.73
Between two biopsies	0.8 (0.2-2.39)	0.7
Decrease of CD4 (> 20% between two biopsies)	4.88 (1.59-15)	0.007
Detectable HIVRNA	5.44 (0.8-36.8)	0.08
Route of HIV transmission (IDU gvs. other)	1.1 (0.2-4.6)	1
CDC h stage (C vs. A or B)	1.7 (0.5-5.4)	0.3

^a OR: Odds ratio

^b CI: Confidence interval

^c ALT: Alanine aminotransferase

^d ART: Antiretroviral therapy

^e NRTIs: Nucleoside reverse transcriptase inhibitors

^f HAART: Highly active antiretroviral therapy

^g IDU: Injecting drug use

^h CDC: Centres for Disease Control and Prevention